This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2014 by National Taiwan University Hospital
Information provided by (Responsible Party):
National Taiwan University Hospital Identifier:
First received: January 17, 2014
Last updated: July 31, 2014
Last verified: July 2014
In this study, we aim to investigate the incidence of the adverse reactions, the effectiveness and the gene polymorphism associated with the plasma level of sulfamethoxazole-trimethoprim and their metabolites (including N4-acetyl-sulfamethoxazole, sulfamethoxazole hydroxylamine and sulfamethoxazole-nitroso). And we also aim to investigate the factors associated with the sulfamethoxazole-trimethoprim induced acute psychosis.

Pneumocystis Jirovecii Pneumonia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • High performance liquid chromatography for drug plasma concentration [ Time Frame: Participants will be followed for the duration of the treatment course, an expected average of 21 days ]
    The plasma concentration will not be measured until the patient's treatment course completed.

Estimated Enrollment: 1000
Study Start Date: January 2014
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Sulfamethoxazole-trimethoprim treatment


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who are treated in the National Taiwan University Hospital

Inclusion Criteria:

  • males and females aged 20 years or older
  • using oral or intravenous form of sulfamethoxazole-trimethoprim

Exclusion Criteria:

  • patients who are under 20 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02045160

Contact: Jin-Han Yang, Bachelor 0975-103-277

National Taiwan University Hospital Active, not recruiting
Taipei, TW, Taiwan, 106
National Taiwan University Hospital Recruiting
Taipei, TW, Taiwan, 106
Contact: Jin-Han Yang   
Principal Investigator: Shu-Wen Lin         
Sponsors and Collaborators
National Taiwan University Hospital
  More Information

Responsible Party: National Taiwan University Hospital Identifier: NCT02045160     History of Changes
Other Study ID Numbers: 201312090RINC
Study First Received: January 17, 2014
Last Updated: July 31, 2014

Additional relevant MeSH terms:
Pneumocystis Infections
Pneumonia, Pneumocystis
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Lung Diseases, Fungal
Trimethoprim, Sulfamethoxazole Drug Combination
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Antiprotozoal Agents
Antiparasitic Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2C8 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Anti-Bacterial Agents processed this record on August 18, 2017